866-997-4948(US-Canada Toll Free)

Amyotrophic Lateral Sclerosis: Epidemiology Forecast to 2027

Published By :

GlobalData

Published Date : Jul 2018

Category :

Pharmaceutical

No. of Pages : 32 Pages

Amyotrophic Lateral Sclerosis: Epidemiology Forecast to 2027

Summary

ALS is a rare but fatal progressive neurodegenerative disease that affects the nerve cells in the brain and the spinal cord (Doi et al., 2014). ALS is often referred to as "Lou Gehrig's Disease" after the famous baseball player. ALS severely impacts physical functioning, and initially presents with muscle twitching, weakness in an arm or leg, or sometimes with slurring of speech. Eventually, people with ALS lose their ability to control the muscles needed to move, speak, eat, and breathe, which ultimately leads to death.

GlobalData epidemiologists used age- and sex-specific diagnosed prevalence rates to forecast the diagnosed prevalent cases, and used the diagnosis rate and diagnosed prevalence to calculate total prevalent cases taking into account the significant relationship between age and ALS prevalence. GlobalData epidemiologists applied country-specific prevalence rates of ALS, wherever available, to each countrys population to obtain the number of estimated diagnosed prevalent cases.

The following data describes epidemiology of ALS cases. In 2017, the 7MM had 46,240 diagnosed prevalent cases of ALS. This is expected to increase to 52,712 diagnosed prevalent cases by 2027, at an Annual Growth Rate (AGR) of 1.40%. The increase is driven by the aging population in the 7MM. In 2017, the 7MM had 53,024 total prevalent cases of ALS. This is expected to increase to 60,304 total prevalent cases by 2027, at an AGR of 1.37%. The US had the highest number of diagnosed prevalent and total prevalent cases of ALS. The development of more effective therapies, particularly for elderly patients, would improve survival and increase disease prevalence.

Scope

- The Amyotrophic Lateral Sclerosis (ALS) Epidemiology Forecast Report provides an overview of the risk factors and global trends of ALS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report also includes a 10-year epidemiological forecast for the following segmentations in ages 40 years and older across the 7MM: 10-year epidemiological forecast for the total (medically diagnosed and undiagnosed) and diagnosed prevalent cases of ALS. The diagnosed prevalent cases are further segmented by age (40 years and older), sex, and type of ALS based on sporadic and familial component.
- The ALS epidemiology forecast report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The ALS Epidemiology Forecast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global ALS market.
- Quantify patient populations in the global ALS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for ALS therapeutics in each of the markets covered.
- Understand proportion of ALS population based on sporadic and familial component.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Amyotrophic Lateral Sclerosis: Executive Summary 4
2.1 Related Reports 5
2.2 Upcoming Reports 5
3 Epidemiology 6
3.1 Disease Background 6
3.2 Risk Factors and Comorbidities 6
3.3 Global and Historical Trends 7
3.3.1 US 9
3.3.2 5EU 9
3.3.3 Japan 10
3.4 Forecast Methodology 10
3.4.1 Sources 11
3.4.2 Forecast Assumptions and Methods 13
3.5 Epidemiological Forecast for ALS (2017-2027) 17
3.5.1 Diagnosed Prevalent Cases of ALS 17
3.5.2 Age-Specific Diagnosed Prevalent Cases of ALS 19
3.5.3 Sex-Specific Diagnosed Prevalent Cases of ALS 20
3.5.4 Diagnosed Prevalent Cases of ALS by Type 21
3.5.5 Total Prevalent Cases of ALS 22
3.6 Discussion 23
3.6.1 Epidemiological Forecast Insight 23
3.6.2 Limitations of Analysis 24
3.6.3 Strengths of Analysis 25
4 Appendix 26
4.1 Primary Research - Prescriber Survey 28
4.2 About the Authors 29
4.2.1 Epidemiologist 29
4.2.2 Reviewers 29
4.2.3 Global Director of Therapy Analysis and Epidemiology 30
4.2.4 Global Head and EVP of Healthcare Operations and Strategy 30
4.3 About GlobalData 31
4.4 Contact Us 31
4.5 Disclaimer 31

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for ALS 7
Table 2: High-Prescribing Physicians (Non-Key Opinion Leaders) Surveyed, By Country 28

1.2 List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of ALS, Both Sexes, Ages 40 Years, 2017 and 2027 5
Figure 2: 7MM, Age-Standardized Diagnosed Prevalence of ALS, Ages 40 Years, 2017 9
Figure 3:Sources Used for Diagnosed Prevalent Cases of ALS 11
Figure 4:Sources Used for Diagnosed Prevalent Cases of ALS Type 12
Figure 5: 7MM, Diagnosed Prevalent Cases of ALS, Men and Women, Ages 40 Years, 2017 18
Figure 6: 7MM, Age-Specific Diagnosed Prevalent Cases of ALS, Men and Women, 2017 19
Figure 7: 7MM, Sex-Specific Diagnosed Prevalent Cases of ALS, Men and Women, Ages 40 Years, 2017 20
Figure 8: 7MM, Diagnosed Prevalent Cases of ALS by Type, Men and Women, Ages 40 Years, 2017 21
Figure 9: 7MM, Total Prevalent Cases of ALS, Men and Women, Ages 40 Years, 2017 22

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *